Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam

Tamma, Pranita D.; Fan, Yunfan; Bergman, Yehudit; Sick-Samuels, Anna; Hsu, Alice J.; Timp, Winston; Simner, Patricia J.; Prokesch, Bonnie C; Greenberg, David E.

doi:10.1128/aac.02213-17

Cited by 33 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…34 A case report of persistent BCC bacteremia in a 2-month-old infant was cleared with ceftazidime-avibactam. 35 Due to limited in vivo evidence, treatment of BCC is largely driven by in vitro data and individual susceptibilities. Therefore, trimethoprimsulfamethoxazole, meropenem, and ceftazidime are first-line agents (Table 6).…”

Section: Clinical Treatment Datamentioning

confidence: 99%

“…64 Due to limited clinical treatment data, literature analyzing in vitro susceptibilities of Achromobacter and Alcaligenes suggests that piperacillin-tazobactam, carbapenems, ceftazidime, or trimethoprim- Trimethoprim-sulfamethoxazole Minocycline Levofloxacin Tigecycline Ceftazidime-avibactam + aztreonam Amoxicillin-clavulanate + aztreonam Burkholderia cepacia complex 2,17,[19][20][21][22][23][24][25][26] Trimethoprim-sulfamethoxazole Meropenem Ceftazidime Minocycline Ceftazidime-avibactam Ceftazidime-avibactam + piperacillin-tazobactam Elizabethkingia spp. 27,30,[35][36][37][38] Combination of any of the below: Minocycline Moxifloxacin, levofloxacin Rifampin Piperacillin-tazobactam Trimethoprim-sulfamethoxazole…”

Section: Clinical Treatment Datamentioning

confidence: 99%

See 1 more Smart Citation

An Overview of the Treatment of Less Common Non–Lactose‐Fermenting Gram‐Negative Bacteria

et al. 2020

View full text Add to dashboard Cite

Stenotrophomonas maltophilia, Burkholderia cepacia complex, Elizabethkingia spp., Chryseobacterium spp., Achromobacter spp., and Alcaligenes spp. are less‐common non–lactose‐fermenting bacteria that have emerged as important opportunistic pathogens. Patients at the highest risk for these infections include the immunocompromised, those with cystic fibrosis, and the critically ill. These opportunistic pathogens are frequently drug resistant through the expression of β‐lactamases, multidrug efflux pumps, aminoglycoside‐modifying enzymes, and target site alterations discussed in detail throughout this review. As a result, treatment is extremely challenging. For each pathogen, this review will examine the epidemiology, mechanisms of resistance, and in vitro and in vivo data including that for novel β‐lactam/β‐lactamase inhibitors and cefiderocol. Treatment recommendations are provided based on the available literature.

show abstract

Section: Clinical Treatment Datamentioning

confidence: 99%

Section: Clinical Treatment Datamentioning

confidence: 99%

An Overview of the Treatment of Less Common Non–Lactose‐Fermenting Gram‐Negative Bacteria

et al. 2020

View full text Add to dashboard Cite

show abstract

“…While there are limited data on the treatment of trimethoprim-sulfamethoxazole-resistant B. cepacia complex, recent anecdotal evidence has suggested that ceftazidime-avibactam may be used successfully. 132 One new drug that may be beneficial for the treatment of drug-resistant S. maltophilia and Burkholderia species includes cefiderocol. 133 As previously noted, cefiderocol is a cephalosporin conjugated with a catechol siderophore and in vitro studies have shown activity against S. maltophilia and Burkholderia species, but once again, additional clinical data are awaited before it can be recommended for use.…”

Section: Mdr-acinetobacter Baumanniimentioning

confidence: 99%

Difficult-to-Treat Antibiotic-Resistant Gram-Negative Pathogens in the Intensive Care Unit: Epidemiology, Outcomes, and Treatment

Strich

Kadri

2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Antibiotic resistance among gram-negative pathogens is a world-wide problem that poses a constant threat to patients in the intensive care unit and a therapeutic challenge for the intensivist. Furthermore, the substantial economic burden and increased mortality associated with infections due to highly resistant gram-negative pathogens exacerbate these challenges. Understanding the mechanisms, epidemiology, and risk factors for these infections is paramount to the successful control of outbreaks and for guiding therapy which often entails use of antibiotics with suboptimal efficacy and/or toxicity profiles. In this review we will discuss the global epidemiology, burden, risk factors, and treatment of highly resistant gram-negative infections as they apply to the intensive care population.

show abstract

“…Based on the results from these trials, the Food and Drug Administration (FDA) has recently approved its use in pediatric patients Ͼ3 months of age with complicated intra-abdominal infections (cIAIs), in conjunction with an agent active against anaerobic organisms, and also those with urinary tract infections (UTIs). Currently, clinical data on the treatment of CRE infections with ceftazidime-avibactam in the pediatric population are limited to a few case reports (32,(75)(76)(77)(78).…”

Section: Treatmentmentioning

confidence: 99%

Carbapenem-Resistant Gram-Negative Bacterial Infections in Children

Aguilera‐Alonso

Escosa-García

Saavedra-Lozano

et al. 2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Carbapenem-resistant organisms (CRO) are a major global public health threat. Enterobacterales hydrolyze almost all β-lactams through carbapenemase production. Infections caused by CRO are challenging to treat due to the limited number of antimicrobial options. This leads to significant morbidity and mortality. Over the last few years, several new antibiotics effective against CRO have been approved. Some of them (e.g., plazomicin or imipenem-cilastatin-relebactam) are currently approved for use only by adults; others (e.g., ceftazidime-avibactam) have recently been approved for use by children. Recommendations for antibiotic therapy of CRO infections in pediatric patients are based on evidence mainly from adult studies. The availability of pediatric pharmacokinetic and safety data is the cornerstone to broaden the use of proposed agents in adults to the pediatric population. This article provides a comprehensive review of the current knowledge regarding infections caused by CRO with a focus on children, which includes epidemiology, risk factors, outcomes, and antimicrobial therapy management, with particular attention being given to new antibiotics.

show abstract

Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam

Cited by 33 publications

References 14 publications

An Overview of the Treatment of Less Common Non–Lactose‐Fermenting Gram‐Negative Bacteria

An Overview of the Treatment of Less Common Non–Lactose‐Fermenting Gram‐Negative Bacteria

Difficult-to-Treat Antibiotic-Resistant Gram-Negative Pathogens in the Intensive Care Unit: Epidemiology, Outcomes, and Treatment

Carbapenem-Resistant Gram-Negative Bacterial Infections in Children

Contact Info

Product

Resources

About